Japan, April 28, 2010 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that its US subsidiary, Astellas Pharma US, Inc.(headquarters: Deerfield, Illinois, “Astellas Pharma US” ) to construct new corporate headquarters for Americas in Glenview, Illinois.
Currently Astellas has several subsidiaries for R&D, manufacturing, sales and marketing in the U.S. Astellas Pharma US has already established a strong business platform in hospitals and medical specialist areas by promoting the pharmaceutical products such as an immunosuppressant Prograf®, a treatment for overactive bladder VESIcare® and an injectable antifungal agent Mycamine®. Astellas has its global development headquarters, Astellas Pharma Global Development, Inc., in the United States to further strengthen its drug development capabilities and competitiveness in the global pharmaceutical market. Astellas has decided to construct the new corporate headquarters to accommodate the company’s growth with ample space and considering other circumstances such as office security and leasing expiring of current buildings.
The new corporate headquarters, which is schedule for completion in the spring of 2012, will be two six-story buildings totaling 425,000 square feet and will cost approximately $150 million.